Skip to content
- AlphaTON shifts focus from biotech to Telegram’s blockchain ecosystem investments.
- Immunova acquires iOx Therapeutics with potential milestone payments over $100M.
- AlphaTON continues biotech development while embracing Telegram-driven technologies.
AlphaTON Capital Corp. (NASDAQ: ATON) is making a bold move, shifting its focus from drug manufacturing to Telegram’s growing blockchain ecosystem. It has also been noted that Immunova has been exercising a call option to obtain iOx Therapeutics Limited, a subsidiary that focuses on liposomal iNKT agonists, a promising field in immuno-oncology. This plan should result in significant economic benefits to AlphaTON, and the transaction is likely to reach over $100 million of milestone payments, royalties, and equity issues.
Also Read: XRP Faces Major Setback: Active Addresses Drop 26% – What’s Behind the Decline?
Strategic Shift from Biotech to Blockchain Investments
The acquisition transaction will result in AlphaTON owning 10% of the fully diluted equity of Immunova, which will value the company in the long term, as well as enable Immunova to implement its complete programs of immune therapies. This move supports a changing stance of AlphaTON to specialize in the areas of digital assets and blockchain investments related to the ecosystem of Telegram. It was also formerly referred to as Portage Biotech Inc., which was a company that specialized in cancer treatment, but its recent shift towards the blockchain world is a significant change in its operation as a firm.
Despite the fact that AlphaTON is selling off its drug production division, it still focuses on the growth of its mesothelioma program. The firm is well placed to start treating its first patient with TT-4, which is a novel therapy for rare cancers. Another way that AlphaTON continues to invest in the Telegram blockchain ecosystem is with applications such as the decentralized Cocoon AI platform, which is yet another indication of its dedication to new technologies.
Positioning for Long-Term Growth in Blockchain and Biotech
This disposal of its biotech business is an essential move for AlphaTON, as it opens value in its iOx division without giving away its long-term involvement in the immuno-oncology segment. Besides, it highlights that the company is strategically oriented towards blockchain and AI-driven biotech, which are regarded as some of the critical areas of expansion in the digital asset and technology industry.
As the Telegram blockchain world keeps growing, AlphaTON is making its mark as a key player in the industry, with a combination of advanced biotech and decentralized technologies. Having invested a substantial amount in the TON token and being a partner in several Telegram-driven projects, the company is speculating on the future of digital assets, enabling it to have a presence in biotech research and continue growing and innovating.
Also Read: Animoca Brands Secures Major Crypto Licence in Dubai, Unlocking Massive Growth!
